Ladostigil (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ladostigil" in English language version.

refsWebsite

Global rank English rank

8nih.gov

4^th place

7doi.org

2^nd place

4semanticscholar.org

11^th place

8^th place

1springer.com

274^th place

309^th place

1archive.today

14^th place

1sagepub.com

731^st place

638^th place

1harvard.edu

18^th place

17^th place

archive.today

Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.

doi.org

Weinstock M, Bejar C, Wang RH, et al. (2000). "TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease". Advances in Research on Neurodegeneration. pp. 157–69. doi:10.1007/978-3-7091-6301-6_10. ISBN 978-3-211-83537-1. PMID 11205137. {{cite book}}: |journal= ignored (help)
Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.
Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics. 6 (1): 163–74. doi:10.1016/j.nurt.2008.10.030. PMC 5084264. PMID 19110207.
Weinstock M, Luques L, Bejar C, Shoham S (2006). "Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression". Parkinson's Disease and Related Disorders. pp. 443–6. doi:10.1007/978-3-211-45295-0_67. ISBN 978-3-211-28927-3. PMID 17017566. {{cite book}}: |journal= ignored (help)
Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences. 1122 (1): 155–68. Bibcode:2007NYASA1122..155W. doi:10.1196/annals.1403.011. PMID 18077571. S2CID 39753711.
Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology. 160 (3): 318–24. doi:10.1007/s00213-001-0978-x. PMID 11889501. S2CID 26001621.
Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry. 27 (4): 555–61. doi:10.1016/S0278-5846(03)00053-8. PMID 12787840. S2CID 21612561.

harvard.edu

ui.adsabs.harvard.edu

Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences. 1122 (1): 155–68. Bibcode:2007NYASA1122..155W. doi:10.1196/annals.1403.011. PMID 18077571. S2CID 39753711.

nih.gov

pubmed.ncbi.nlm.nih.gov

Weinstock M, Bejar C, Wang RH, et al. (2000). "TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease". Advances in Research on Neurodegeneration. pp. 157–69. doi:10.1007/978-3-7091-6301-6_10. ISBN 978-3-211-83537-1. PMID 11205137. {{cite book}}: |journal= ignored (help)
Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.
Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics. 6 (1): 163–74. doi:10.1016/j.nurt.2008.10.030. PMC 5084264. PMID 19110207.
Weinstock M, Luques L, Bejar C, Shoham S (2006). "Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression". Parkinson's Disease and Related Disorders. pp. 443–6. doi:10.1007/978-3-211-45295-0_67. ISBN 978-3-211-28927-3. PMID 17017566. {{cite book}}: |journal= ignored (help)
Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences. 1122 (1): 155–68. Bibcode:2007NYASA1122..155W. doi:10.1196/annals.1403.011. PMID 18077571. S2CID 39753711.
Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology. 160 (3): 318–24. doi:10.1007/s00213-001-0978-x. PMID 11889501. S2CID 26001621.
Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry. 27 (4): 555–61. doi:10.1016/S0278-5846(03)00053-8. PMID 12787840. S2CID 21612561.

ncbi.nlm.nih.gov

Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics. 6 (1): 163–74. doi:10.1016/j.nurt.2008.10.030. PMC 5084264. PMID 19110207.

sagepub.com

jcp.sagepub.com

Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.

semanticscholar.org

api.semanticscholar.org

Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.
Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences. 1122 (1): 155–68. Bibcode:2007NYASA1122..155W. doi:10.1196/annals.1403.011. PMID 18077571. S2CID 39753711.
Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology. 160 (3): 318–24. doi:10.1007/s00213-001-0978-x. PMID 11889501. S2CID 26001621.
Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry. 27 (4): 555–61. doi:10.1016/S0278-5846(03)00053-8. PMID 12787840. S2CID 21612561.

springer.com

adisinsight.springer.com

"Ladostigil - Avraham Pharmaceuticals". AdisInsight. 3 August 2022. Retrieved 17 August 2024.